These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
4. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role? Mukherjee D; Roffi M J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343 [No Abstract] [Full Text] [Related]
5. Use of abciximab in interventional cardiology. Chronos N; Vahanian A; Betriu A; Emanuelsson H; Goldberg S; Gulba D; van Hout BA Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520 [TBL] [Abstract][Full Text] [Related]
6. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]